array:23 [
  "pii" => "S1578219019302227"
  "issn" => "15782190"
  "doi" => "10.1016/j.adengl.2018.12.012"
  "estado" => "S300"
  "fechaPublicacion" => "2019-09-01"
  "aid" => "2130"
  "copyright" => "Elsevier España, S.L.U. and AEDV"
  "copyrightAnyo" => "2018"
  "documento" => "simple-article"
  "crossmark" => 1
  "subdocumento" => "cor"
  "cita" => "Actas Dermosifiliogr. 2019;110:517-8"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:1 [
    "total" => 0
  ]
  "Traduccion" => array:1 [
    "es" => array:19 [
      "pii" => "S0001731018305751"
      "issn" => "00017310"
      "doi" => "10.1016/j.ad.2018.12.002"
      "estado" => "S300"
      "fechaPublicacion" => "2019-09-01"
      "aid" => "2130"
      "copyright" => "AEDV"
      "documento" => "simple-article"
      "crossmark" => 1
      "subdocumento" => "cor"
      "cita" => "Actas Dermosifiliogr. 2019;110:517-8"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:2 [
        "total" => 263
        "formatos" => array:2 [
          "HTML" => 179
          "PDF" => 84
        ]
      ]
      "es" => array:10 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">Comentarios Editoriales</span>"
        "titulo" => "An&#225;lisis del coste incremental por respondedor &#40;PASI75&#44; PASI90 y PASI100&#41; basado en un metaan&#225;lisis en red de tratamientos biol&#243;gicos para la psoriasis&#58; Espa&#241;a 2018"
        "tienePdf" => "es"
        "tieneTextoCompleto" => "es"
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "517"
            "paginaFinal" => "518"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "en" => array:1 [
            "titulo" => "Incremental Cost per Responder &#40;PASI-75&#44; PASI-90 and PASI-100&#41; Based on a Network Meta-Analysis of Biologic Therapies for Psoriasis&#58; Spain 2018"
          ]
        ]
        "contieneTextoCompleto" => array:1 [
          "es" => true
        ]
        "contienePdf" => array:1 [
          "es" => true
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "L&#46; Puig"
            "autores" => array:1 [
              0 => array:2 [
                "nombre" => "L&#46;"
                "apellidos" => "Puig"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "es"
      "Traduccion" => array:1 [
        "en" => array:9 [
          "pii" => "S1578219019302227"
          "doi" => "10.1016/j.adengl.2018.12.012"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => true
            "ES2" => true
            "LATM" => true
          ]
          "gratuito" => true
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "en"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219019302227?idApp=UINPBA000044"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731018305751?idApp=UINPBA000044"
      "url" => "/00017310/0000011000000007/v1_201909021023/S0001731018305751/v1_201909021023/es/main.assets"
    ]
  ]
  "itemSiguiente" => array:19 [
    "pii" => "S1578219019302094"
    "issn" => "15782190"
    "doi" => "10.1016/j.adengl.2019.05.014"
    "estado" => "S300"
    "fechaPublicacion" => "2019-09-01"
    "aid" => "2228"
    "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46; and AEDV"
    "documento" => "simple-article"
    "crossmark" => 1
    "subdocumento" => "cor"
    "cita" => "Actas Dermosifiliogr. 2019;110:518-9"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 1
      "HTML" => 1
    ]
    "en" => array:10 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Comentarios Editoriales</span>"
      "titulo" => "Patient-Reported Outcomes in Psoriasis Validated in Spain&#58; PROs and Cons"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "518"
          "paginaFinal" => "519"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Patient reported outcomes en psoriasis validados en Espa&#241;a&#58; PROs y contras"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "L&#46; Puig"
          "autores" => array:1 [
            0 => array:2 [
              "nombre" => "L&#46;"
              "apellidos" => "Puig"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "S0001731019301930"
        "doi" => "10.1016/j.ad.2019.05.001"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731019301930?idApp=UINPBA000044"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219019302094?idApp=UINPBA000044"
    "url" => "/15782190/0000011000000007/v1_201909021030/S1578219019302094/v1_201909021030/en/main.assets"
  ]
  "en" => array:13 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Commentaries</span>"
    "titulo" => "Incremental Cost per Responder &#40;PASI-75&#44; PASI-90 and PASI-100&#41; Based on a Network Meta-Analysis of Biologic Therapies for Psoriasis&#58; Spain 2018"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "517"
        "paginaFinal" => "518"
      ]
    ]
    "autores" => array:1 [
      0 => array:3 [
        "autoresLista" => "L&#46; Puig"
        "autores" => array:1 [
          0 => array:3 [
            "nombre" => "L&#46;"
            "apellidos" => "Puig"
            "email" => array:1 [
              0 => "lpuig@santpau.cat"
            ]
          ]
        ]
        "afiliaciones" => array:1 [
          0 => array:2 [
            "entidad" => "Servicio de Dermatolog&#237;a&#44; Hospital de la Santa Creu i Sant Pau&#44; Barcelona&#44; Spain"
            "identificador" => "aff0005"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "An&#225;lisis del coste incremental por respondedor &#40;PASI75&#44; PASI90 y PASI100&#41; basado en un metaan&#225;lisis en red de tratamientos biol&#243;gicos para la psoriasis&#58; Espa&#241;a 2018"
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">An&#225;lisis del coste incremental por respondedor &#40;PASI75&#44; PASI90 y PASI100&#41; basado en un metaan&#225;lisis en red de tratamientos biol&#243;gicos para la psoriasis&#58; Espa&#241;a 2018</p><p id="par0010" class="elsevierStylePara elsevierViewall">Incremental Cost per Responder &#40;PASI-75&#44; PASI-90 and PASI-100&#41; Based on a Network Meta-Analysis of Biologic Therapies for Psoriasis&#58; Spain 2018</p><p id="par0015" class="elsevierStylePara elsevierViewall">Network meta-analysis&#44; which now has a well-established methodology&#44; provides information on the relative efficacy of a number of treatments using data from clinical trials that directly compare two or more drugs in addition to indirect comparisons based on data from different trials using the same comparator&#46; Variations between trials are adjusted to the reference arm response rates&#46; Meta-analysis results can be expressed as the differential response compared to placebo &#40;either as a percentage or its corresponding decimal value&#41; or as its inverse&#8212;the number needed to treat &#40;NNT&#41;&#44; that is&#44; the number of patients that must be treated to achieve a responder&#46; The NNT and the incremental cost per responder&#8212;calculated by multiplying the NNT for the drug by the cost for the period considered&#8212;provide reliable values that allow us to compare the expected effectiveness of different treatments at various response levels&#44; a datum with important clinical and economic implications for physicians and those responsible for making decisions on treatment funding and reimbursement&#46;</p><p id="par0020" class="elsevierStylePara elsevierViewall">The objective of the study in this issue<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">1</span></a> was to evaluate the cost-effectiveness of ixekizumab as afirst-line biologic for the treatment of psoriasis and to compare it with that of other biologic agents based on data from a recently published network meta-analysis&#46;<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">2</span></a> Employees of the company that markets ixekizumab were involved in carrying out the network meta-analysis&#46; The main interest of the article is that it is the first study to provide data on ixekizumab in Spain&#46; In addition to the information provided by the health technology agencies&#39; assessments&#44; a study similar to this one has recently been published in the United States&#46;<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">3</span></a></p><p id="par0025" class="elsevierStylePara elsevierViewall">The methodology and results of the study are valid&#44; but the terminology used for the outcome of interest &#40;&#8220;cost per NNT&#8221;&#41; is debatable&#58; it would probably be preferable to use the expression &#8220;&#40;incremental&#41; cost per successfully treated patient&#8221;&#46; The cost per NNT values &#40;cost x NNT&#41; corresponding to each response level are calculated by multiplying the cost of treatment by the respective NNT value &#40;and the 95&#37; credible interval&#41;&#46; However&#44; by analogy with widely used concepts such as &#8220;cost per patient&#8221; or &#8220;cost per day&#8221;&#44; the term &#8220;cost per NNT&#8221; suggests that the NNT is dividing &#40;cost&#47;NNT&#41; rather than multiplying the cost&#46; The term <span class="elsevierStyleItalic">incremental</span> is not relevant in this particular case because the cost of placebo is considered to be zero&#46;</p><p id="par0030" class="elsevierStylePara elsevierViewall">In the analysis by N&#250;&#241;ez et al&#46;<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">1</span></a> the population corresponds to the Summaries of Product Characteristics&#44; in each case&#44; and treatment response is expressed as the percentage of reduction in the Psoriasis Area and Severity Index &#40;PASI&#41; with respect to baseline&#44; with 3 different levels of efficacy &#40;PASI 75&#44; PASI 90 and PASI 100&#41;&#46; The cost per responder is calculated by multiplying the annual cost &#40;or the cost up to the end of the comparative phase vs placebo&#44; the <span class="elsevierStyleItalic">endpoint</span> in the clinical trials&#41; by the NNT&#46; In the meta-analysis&#44; the authors assume that the efficacy at that point is the same as the short-term effectiveness maintained&#44; without loss&#44; for the whole year&#46; The 95&#37; credible interval is not given for most of the results reported in the article&#46; This decision may have been taken to improve readibility&#44; but the use of the &#34;greater than&#34; symbol &#40;&#62;&#41; for comparisons may lead to confusion&#58; although the incremental cost per responder central values differ numerically&#44; one cannot strictly talk about the superiority of one drug over another when their credible intervals overlap&#46;</p><p id="par0035" class="elsevierStylePara elsevierViewall">The model used does not address the response rate achieved by each biologic agent as a rescue treatment or possible differences in the response of patients with a history of prior exposure or treatment failure with other biologic agents &#40;generally unknown or assumed to be similar or inferior in a variable and drug-dependent percentage to the response of patients who have never received biologic therapy&#41;&#46; Neither does it take into account drop-out rates&#44; indirect treatment costs&#44; or possible complications&#46; The authors could also have included apremilast&#44; which&#44; while not a biologic agent&#44; has a similar acquisition cost&#46;</p><p id="par0040" class="elsevierStylePara elsevierViewall">More complex models have been proposed based on periods of 52 weeks<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">4</span></a> and 2 years&#46;<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">5</span></a> One difference between those 2 studies is the choice of rescue treatment for patients who experience treatment failure &#40;conventional systemic treatment or phototherapy in the German model<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">4</span></a>&#41;&#46; In the study that considers the perspective of the Spanish health system&#44;<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">5</span></a> with a 2-year time horizon&#44; indirect costs were not taken into account and assumptions were made regarding the rates of treatment intensification and switches to other biologic treatments as well as the cost-effectiveness of these interventions&#46; The order of efficiency reported in that study differs from that reported in the study in this issue&#46;</p><p id="par0045" class="elsevierStylePara elsevierViewall">Despite its limitations&#44; which actually represent possible alternative approaches&#44; the study is interesting and informative&#46; The methodology is correct &#40;there is always room for debate about whether or not the last dose should be included in the calculation of the interval or apportioned&#41; and the inclusion of a sensitivity analysis based on the results corresponding to the endpoint for each drug &#40;ranging from 10 to 16 weeks&#41; is appropriate&#44; with the limitation of between-trial differences in the duration of that period&#46; The usefulness of this article could be greatly enhanced through the inclusion&#44; as an on-line supplement&#44; of an Excel sheet or a link where the reader could access or download a small Java&#44; Android or Apple application&#44; depending on the platform&#46; This application would enable clinicians or pharmacists to calculate the results for the specific situation of each hospital &#40;given the current highly variable and fluid pricing situation&#41; and to incorporate new drugs as they become available&#44; and even modify the NNT data as new meta-analyses are published&#46;</p><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0005">Conflicts of Interest</span><p id="par0050" class="elsevierStylePara elsevierViewall">L&#46; Puig has received fees as a consultant or lecturer and&#47;or has served as a researcher in clinical trials sponsored by&#58; Abbvie&#44; Almirall&#44; Amgen&#44; Baxalta&#44; Biogen&#44; Boehringer Ingelheim&#44; Celgene&#44; Gebro&#44; Janssen&#44; Leo-Pharma&#44; Lilly&#44; Merck-Serono&#44; MSD&#44; Mylan&#44; Novartis&#44; Pfizer&#44; Regeneron&#44; Roche&#44; Sandoz&#44; Samsung-Bioepis&#44; Sanofi and UCB&#46;</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:2 [
        0 => array:2 [
          "identificador" => "sec0005"
          "titulo" => "Conflicts of Interest"
        ]
        1 => array:1 [
          "titulo" => "References"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "NotaPie" => array:1 [
      0 => array:2 [
        "etiqueta" => "&#9734;"
        "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as&#58; Puig L&#46; An&#225;lisis del coste incremental por respondedor &#40;PASI75&#44; PASI90 y PASI100&#41; basado en un metaan&#225;lisis en red de tratamientos biol&#243;gicos para la psoriasis&#58; Espa&#241;a 2018&#46; Actas Dermosifiliogr&#46; 2019&#59;110&#58;517&#8211;518&#46;</p>"
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "References"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0015"
          "bibliografiaReferencia" => array:5 [
            0 => array:3 [
              "identificador" => "bib0030"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Evaluaci&#243;n de la eficiencia de los tratamientos biol&#243;gicos en la psoriasis moderada a grave en Espa&#241;a&#58; An&#225;lisis de coste por NNT"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "M&#46; N&#250;&#241;ez"
                            1 => "T&#46; Huete"
                            2 => "P&#46; de la Cueva"
                            3 => "J&#46;A&#46; Sacrist&#225;n"
                            4 => "S&#46; Hartz"
                            5 => "T&#46; Dilla"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:2 [
                        "tituloSerie" => "Actas Dermosifiliogr"
                        "fecha" => "2018"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0035"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "S&#46; Al Sawah"
                            1 => "S&#46;A&#46; Foster"
                            2 => "R&#46; Burge"
                            3 => "D&#46; Amato"
                            4 => "A&#46; Schacht"
                            5 => "B&#46; Zhu"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1080/13696998.2017.1362413"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Med Econ"
                        "fecha" => "2017"
                        "volumen" => "20"
                        "paginaInicial" => "1224"
                        "paginaFinal" => "1230"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28760056"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0040"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Number needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis&#58; A network meta-analysis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "A&#46;W&#46; Armstrong"
                            1 => "K&#46;A&#46; Betts"
                            2 => "J&#46;E&#46; Signorovitch"
                            3 => "M&#46; Sundaram"
                            4 => "J&#46; Li"
                            5 => "A&#46;X&#46; Ganguli"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1080/03007995.2018.1457516"
                      "Revista" => array:6 [
                        "tituloSerie" => "Curr Med Res Opin"
                        "fecha" => "2018"
                        "volumen" => "34"
                        "paginaInicial" => "1325"
                        "paginaFinal" => "1333"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29619856"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0045"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cost-effectiveness of secukinumab as first biologic treatment&#44; compared with other biologics&#44; for moderate to severe psoriasis in Germany"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "M&#46; Augustin"
                            1 => "D&#46; McBride"
                            2 => "I&#46; Gilloteau"
                            3 => "C&#46; O&#8217;Neill"
                            4 => "K&#46; Neidhardt"
                            5 => "C&#46;N&#46; Graham"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/jdv.15047"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Eur Acad Dermatol Venereol"
                        "fecha" => "2018"
                        "volumen" => "32"
                        "paginaInicial" => "2191"
                        "paginaFinal" => "2199"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29729105"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0050"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Secukinumab is the most efficient treatment for achieving clear skin in psoriatic patients&#58; A cost-consequence study from the Spanish National Health Service"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "L&#46; Puig"
                            1 => "J&#46; Notario"
                            2 => "A&#46; Jimenez-Morales"
                            3 => "D&#46; Moreno-Ram&#237;rez"
                            4 => "A&#46; L&#243;pez-Ferrer"
                            5 => "I&#46; Gozalbo"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1080/09546634.2017.1364687"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Dermatolog Treat"
                        "fecha" => "2017"
                        "volumen" => "28"
                        "paginaInicial" => "623"
                        "paginaFinal" => "630"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28784002"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/15782190/0000011000000007/v1_201909021030/S1578219019302227/v1_201909021030/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "66476"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Commentaries"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/15782190/0000011000000007/v1_201909021030/S1578219019302227/v1_201909021030/en/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219019302227?idApp=UINPBA000044"
]
Compartir
Información de la revista

Estadísticas

Siga este enlace para acceder al texto completo del artículo

Commentaries
Incremental Cost per Responder (PASI-75, PASI-90 and PASI-100) Based on a Network Meta-Analysis of Biologic Therapies for Psoriasis: Spain 2018
Análisis del coste incremental por respondedor (PASI75, PASI90 y PASI100) basado en un metaanálisis en red de tratamientos biológicos para la psoriasis: España 2018
L. Puig
Servicio de Dermatología, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Leído
4725
Veces
se ha leído el artículo
1624
Total PDF
3101
Total HTML
Compartir estadísticas
 array:23 [
  "pii" => "S1578219019302227"
  "issn" => "15782190"
  "doi" => "10.1016/j.adengl.2018.12.012"
  "estado" => "S300"
  "fechaPublicacion" => "2019-09-01"
  "aid" => "2130"
  "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46; and AEDV"
  "copyrightAnyo" => "2018"
  "documento" => "simple-article"
  "crossmark" => 1
  "subdocumento" => "cor"
  "cita" => "Actas Dermosifiliogr. 2019;110:517-8"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:1 [
    "total" => 0
  ]
  "Traduccion" => array:1 [
    "es" => array:19 [
      "pii" => "S0001731018305751"
      "issn" => "00017310"
      "doi" => "10.1016/j.ad.2018.12.002"
      "estado" => "S300"
      "fechaPublicacion" => "2019-09-01"
      "aid" => "2130"
      "copyright" => "AEDV"
      "documento" => "simple-article"
      "crossmark" => 1
      "subdocumento" => "cor"
      "cita" => "Actas Dermosifiliogr. 2019;110:517-8"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:2 [
        "total" => 263
        "formatos" => array:2 [
          "HTML" => 179
          "PDF" => 84
        ]
      ]
      "es" => array:10 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">Comentarios Editoriales</span>"
        "titulo" => "An&#225;lisis del coste incremental por respondedor &#40;PASI75&#44; PASI90 y PASI100&#41; basado en un metaan&#225;lisis en red de tratamientos biol&#243;gicos para la psoriasis&#58; Espa&#241;a 2018"
        "tienePdf" => "es"
        "tieneTextoCompleto" => "es"
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "517"
            "paginaFinal" => "518"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "en" => array:1 [
            "titulo" => "Incremental Cost per Responder &#40;PASI-75&#44; PASI-90 and PASI-100&#41; Based on a Network Meta-Analysis of Biologic Therapies for Psoriasis&#58; Spain 2018"
          ]
        ]
        "contieneTextoCompleto" => array:1 [
          "es" => true
        ]
        "contienePdf" => array:1 [
          "es" => true
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "L&#46; Puig"
            "autores" => array:1 [
              0 => array:2 [
                "nombre" => "L&#46;"
                "apellidos" => "Puig"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "es"
      "Traduccion" => array:1 [
        "en" => array:9 [
          "pii" => "S1578219019302227"
          "doi" => "10.1016/j.adengl.2018.12.012"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => true
            "ES2" => true
            "LATM" => true
          ]
          "gratuito" => true
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "en"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219019302227?idApp=UINPBA000044"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731018305751?idApp=UINPBA000044"
      "url" => "/00017310/0000011000000007/v1_201909021023/S0001731018305751/v1_201909021023/es/main.assets"
    ]
  ]
  "itemSiguiente" => array:19 [
    "pii" => "S1578219019302094"
    "issn" => "15782190"
    "doi" => "10.1016/j.adengl.2019.05.014"
    "estado" => "S300"
    "fechaPublicacion" => "2019-09-01"
    "aid" => "2228"
    "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46; and AEDV"
    "documento" => "simple-article"
    "crossmark" => 1
    "subdocumento" => "cor"
    "cita" => "Actas Dermosifiliogr. 2019;110:518-9"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 1
      "HTML" => 1
    ]
    "en" => array:10 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Comentarios Editoriales</span>"
      "titulo" => "Patient-Reported Outcomes in Psoriasis Validated in Spain&#58; PROs and Cons"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "518"
          "paginaFinal" => "519"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Patient reported outcomes en psoriasis validados en Espa&#241;a&#58; PROs y contras"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "L&#46; Puig"
          "autores" => array:1 [
            0 => array:2 [
              "nombre" => "L&#46;"
              "apellidos" => "Puig"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "S0001731019301930"
        "doi" => "10.1016/j.ad.2019.05.001"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731019301930?idApp=UINPBA000044"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219019302094?idApp=UINPBA000044"
    "url" => "/15782190/0000011000000007/v1_201909021030/S1578219019302094/v1_201909021030/en/main.assets"
  ]
  "en" => array:13 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Commentaries</span>"
    "titulo" => "Incremental Cost per Responder &#40;PASI-75&#44; PASI-90 and PASI-100&#41; Based on a Network Meta-Analysis of Biologic Therapies for Psoriasis&#58; Spain 2018"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "517"
        "paginaFinal" => "518"
      ]
    ]
    "autores" => array:1 [
      0 => array:3 [
        "autoresLista" => "L&#46; Puig"
        "autores" => array:1 [
          0 => array:3 [
            "nombre" => "L&#46;"
            "apellidos" => "Puig"
            "email" => array:1 [
              0 => "lpuig@santpau.cat"
            ]
          ]
        ]
        "afiliaciones" => array:1 [
          0 => array:2 [
            "entidad" => "Servicio de Dermatolog&#237;a&#44; Hospital de la Santa Creu i Sant Pau&#44; Barcelona&#44; Spain"
            "identificador" => "aff0005"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "An&#225;lisis del coste incremental por respondedor &#40;PASI75&#44; PASI90 y PASI100&#41; basado en un metaan&#225;lisis en red de tratamientos biol&#243;gicos para la psoriasis&#58; Espa&#241;a 2018"
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">An&#225;lisis del coste incremental por respondedor &#40;PASI75&#44; PASI90 y PASI100&#41; basado en un metaan&#225;lisis en red de tratamientos biol&#243;gicos para la psoriasis&#58; Espa&#241;a 2018</p><p id="par0010" class="elsevierStylePara elsevierViewall">Incremental Cost per Responder &#40;PASI-75&#44; PASI-90 and PASI-100&#41; Based on a Network Meta-Analysis of Biologic Therapies for Psoriasis&#58; Spain 2018</p><p id="par0015" class="elsevierStylePara elsevierViewall">Network meta-analysis&#44; which now has a well-established methodology&#44; provides information on the relative efficacy of a number of treatments using data from clinical trials that directly compare two or more drugs in addition to indirect comparisons based on data from different trials using the same comparator&#46; Variations between trials are adjusted to the reference arm response rates&#46; Meta-analysis results can be expressed as the differential response compared to placebo &#40;either as a percentage or its corresponding decimal value&#41; or as its inverse&#8212;the number needed to treat &#40;NNT&#41;&#44; that is&#44; the number of patients that must be treated to achieve a responder&#46; The NNT and the incremental cost per responder&#8212;calculated by multiplying the NNT for the drug by the cost for the period considered&#8212;provide reliable values that allow us to compare the expected effectiveness of different treatments at various response levels&#44; a datum with important clinical and economic implications for physicians and those responsible for making decisions on treatment funding and reimbursement&#46;</p><p id="par0020" class="elsevierStylePara elsevierViewall">The objective of the study in this issue<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">1</span></a> was to evaluate the cost-effectiveness of ixekizumab as afirst-line biologic for the treatment of psoriasis and to compare it with that of other biologic agents based on data from a recently published network meta-analysis&#46;<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">2</span></a> Employees of the company that markets ixekizumab were involved in carrying out the network meta-analysis&#46; The main interest of the article is that it is the first study to provide data on ixekizumab in Spain&#46; In addition to the information provided by the health technology agencies&#39; assessments&#44; a study similar to this one has recently been published in the United States&#46;<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">3</span></a></p><p id="par0025" class="elsevierStylePara elsevierViewall">The methodology and results of the study are valid&#44; but the terminology used for the outcome of interest &#40;&#8220;cost per NNT&#8221;&#41; is debatable&#58; it would probably be preferable to use the expression &#8220;&#40;incremental&#41; cost per successfully treated patient&#8221;&#46; The cost per NNT values &#40;cost x NNT&#41; corresponding to each response level are calculated by multiplying the cost of treatment by the respective NNT value &#40;and the 95&#37; credible interval&#41;&#46; However&#44; by analogy with widely used concepts such as &#8220;cost per patient&#8221; or &#8220;cost per day&#8221;&#44; the term &#8220;cost per NNT&#8221; suggests that the NNT is dividing &#40;cost&#47;NNT&#41; rather than multiplying the cost&#46; The term <span class="elsevierStyleItalic">incremental</span> is not relevant in this particular case because the cost of placebo is considered to be zero&#46;</p><p id="par0030" class="elsevierStylePara elsevierViewall">In the analysis by N&#250;&#241;ez et al&#46;<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">1</span></a> the population corresponds to the Summaries of Product Characteristics&#44; in each case&#44; and treatment response is expressed as the percentage of reduction in the Psoriasis Area and Severity Index &#40;PASI&#41; with respect to baseline&#44; with 3 different levels of efficacy &#40;PASI 75&#44; PASI 90 and PASI 100&#41;&#46; The cost per responder is calculated by multiplying the annual cost &#40;or the cost up to the end of the comparative phase vs placebo&#44; the <span class="elsevierStyleItalic">endpoint</span> in the clinical trials&#41; by the NNT&#46; In the meta-analysis&#44; the authors assume that the efficacy at that point is the same as the short-term effectiveness maintained&#44; without loss&#44; for the whole year&#46; The 95&#37; credible interval is not given for most of the results reported in the article&#46; This decision may have been taken to improve readibility&#44; but the use of the &#34;greater than&#34; symbol &#40;&#62;&#41; for comparisons may lead to confusion&#58; although the incremental cost per responder central values differ numerically&#44; one cannot strictly talk about the superiority of one drug over another when their credible intervals overlap&#46;</p><p id="par0035" class="elsevierStylePara elsevierViewall">The model used does not address the response rate achieved by each biologic agent as a rescue treatment or possible differences in the response of patients with a history of prior exposure or treatment failure with other biologic agents &#40;generally unknown or assumed to be similar or inferior in a variable and drug-dependent percentage to the response of patients who have never received biologic therapy&#41;&#46; Neither does it take into account drop-out rates&#44; indirect treatment costs&#44; or possible complications&#46; The authors could also have included apremilast&#44; which&#44; while not a biologic agent&#44; has a similar acquisition cost&#46;</p><p id="par0040" class="elsevierStylePara elsevierViewall">More complex models have been proposed based on periods of 52 weeks<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">4</span></a> and 2 years&#46;<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">5</span></a> One difference between those 2 studies is the choice of rescue treatment for patients who experience treatment failure &#40;conventional systemic treatment or phototherapy in the German model<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">4</span></a>&#41;&#46; In the study that considers the perspective of the Spanish health system&#44;<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">5</span></a> with a 2-year time horizon&#44; indirect costs were not taken into account and assumptions were made regarding the rates of treatment intensification and switches to other biologic treatments as well as the cost-effectiveness of these interventions&#46; The order of efficiency reported in that study differs from that reported in the study in this issue&#46;</p><p id="par0045" class="elsevierStylePara elsevierViewall">Despite its limitations&#44; which actually represent possible alternative approaches&#44; the study is interesting and informative&#46; The methodology is correct &#40;there is always room for debate about whether or not the last dose should be included in the calculation of the interval or apportioned&#41; and the inclusion of a sensitivity analysis based on the results corresponding to the endpoint for each drug &#40;ranging from 10 to 16 weeks&#41; is appropriate&#44; with the limitation of between-trial differences in the duration of that period&#46; The usefulness of this article could be greatly enhanced through the inclusion&#44; as an on-line supplement&#44; of an Excel sheet or a link where the reader could access or download a small Java&#44; Android or Apple application&#44; depending on the platform&#46; This application would enable clinicians or pharmacists to calculate the results for the specific situation of each hospital &#40;given the current highly variable and fluid pricing situation&#41; and to incorporate new drugs as they become available&#44; and even modify the NNT data as new meta-analyses are published&#46;</p><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0005">Conflicts of Interest</span><p id="par0050" class="elsevierStylePara elsevierViewall">L&#46; Puig has received fees as a consultant or lecturer and&#47;or has served as a researcher in clinical trials sponsored by&#58; Abbvie&#44; Almirall&#44; Amgen&#44; Baxalta&#44; Biogen&#44; Boehringer Ingelheim&#44; Celgene&#44; Gebro&#44; Janssen&#44; Leo-Pharma&#44; Lilly&#44; Merck-Serono&#44; MSD&#44; Mylan&#44; Novartis&#44; Pfizer&#44; Regeneron&#44; Roche&#44; Sandoz&#44; Samsung-Bioepis&#44; Sanofi and UCB&#46;</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:2 [
        0 => array:2 [
          "identificador" => "sec0005"
          "titulo" => "Conflicts of Interest"
        ]
        1 => array:1 [
          "titulo" => "References"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "NotaPie" => array:1 [
      0 => array:2 [
        "etiqueta" => "&#9734;"
        "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as&#58; Puig L&#46; An&#225;lisis del coste incremental por respondedor &#40;PASI75&#44; PASI90 y PASI100&#41; basado en un metaan&#225;lisis en red de tratamientos biol&#243;gicos para la psoriasis&#58; Espa&#241;a 2018&#46; Actas Dermosifiliogr&#46; 2019&#59;110&#58;517&#8211;518&#46;</p>"
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "References"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0015"
          "bibliografiaReferencia" => array:5 [
            0 => array:3 [
              "identificador" => "bib0030"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Evaluaci&#243;n de la eficiencia de los tratamientos biol&#243;gicos en la psoriasis moderada a grave en Espa&#241;a&#58; An&#225;lisis de coste por NNT"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "M&#46; N&#250;&#241;ez"
                            1 => "T&#46; Huete"
                            2 => "P&#46; de la Cueva"
                            3 => "J&#46;A&#46; Sacrist&#225;n"
                            4 => "S&#46; Hartz"
                            5 => "T&#46; Dilla"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:2 [
                        "tituloSerie" => "Actas Dermosifiliogr"
                        "fecha" => "2018"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0035"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "S&#46; Al Sawah"
                            1 => "S&#46;A&#46; Foster"
                            2 => "R&#46; Burge"
                            3 => "D&#46; Amato"
                            4 => "A&#46; Schacht"
                            5 => "B&#46; Zhu"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1080/13696998.2017.1362413"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Med Econ"
                        "fecha" => "2017"
                        "volumen" => "20"
                        "paginaInicial" => "1224"
                        "paginaFinal" => "1230"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28760056"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0040"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Number needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis&#58; A network meta-analysis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "A&#46;W&#46; Armstrong"
                            1 => "K&#46;A&#46; Betts"
                            2 => "J&#46;E&#46; Signorovitch"
                            3 => "M&#46; Sundaram"
                            4 => "J&#46; Li"
                            5 => "A&#46;X&#46; Ganguli"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1080/03007995.2018.1457516"
                      "Revista" => array:6 [
                        "tituloSerie" => "Curr Med Res Opin"
                        "fecha" => "2018"
                        "volumen" => "34"
                        "paginaInicial" => "1325"
                        "paginaFinal" => "1333"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29619856"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0045"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cost-effectiveness of secukinumab as first biologic treatment&#44; compared with other biologics&#44; for moderate to severe psoriasis in Germany"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "M&#46; Augustin"
                            1 => "D&#46; McBride"
                            2 => "I&#46; Gilloteau"
                            3 => "C&#46; O&#8217;Neill"
                            4 => "K&#46; Neidhardt"
                            5 => "C&#46;N&#46; Graham"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/jdv.15047"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Eur Acad Dermatol Venereol"
                        "fecha" => "2018"
                        "volumen" => "32"
                        "paginaInicial" => "2191"
                        "paginaFinal" => "2199"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29729105"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0050"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Secukinumab is the most efficient treatment for achieving clear skin in psoriatic patients&#58; A cost-consequence study from the Spanish National Health Service"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "L&#46; Puig"
                            1 => "J&#46; Notario"
                            2 => "A&#46; Jimenez-Morales"
                            3 => "D&#46; Moreno-Ram&#237;rez"
                            4 => "A&#46; L&#243;pez-Ferrer"
                            5 => "I&#46; Gozalbo"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1080/09546634.2017.1364687"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Dermatolog Treat"
                        "fecha" => "2017"
                        "volumen" => "28"
                        "paginaInicial" => "623"
                        "paginaFinal" => "630"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28784002"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/15782190/0000011000000007/v1_201909021030/S1578219019302227/v1_201909021030/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "66476"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Commentaries"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/15782190/0000011000000007/v1_201909021030/S1578219019302227/v1_201909021030/en/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219019302227?idApp=UINPBA000044"
]
Información del artículo
ISSN: 15782190
Idioma original: Inglés
Datos actualizados diariamente
año/Mes Html Pdf Total
2024 Noviembre 14 11 25
2024 Octubre 107 45 152
2024 Septiembre 100 28 128
2024 Agosto 117 64 181
2024 Julio 90 31 121
2024 Junio 92 28 120
2024 Mayo 91 39 130
2024 Abril 90 17 107
2024 Marzo 79 27 106
2024 Febrero 93 38 131
2024 Enero 74 39 113
2023 Diciembre 46 23 69
2023 Noviembre 90 30 120
2023 Octubre 83 26 109
2023 Septiembre 70 25 95
2023 Agosto 37 17 54
2023 Julio 58 33 91
2023 Junio 54 19 73
2023 Mayo 55 28 83
2023 Abril 48 17 65
2023 Marzo 62 30 92
2023 Febrero 39 19 58
2023 Enero 31 27 58
2022 Diciembre 66 46 112
2022 Noviembre 35 30 65
2022 Octubre 23 23 46
2022 Septiembre 20 51 71
2022 Agosto 25 34 59
2022 Julio 24 43 67
2022 Junio 24 25 49
2022 Mayo 71 44 115
2022 Abril 63 39 102
2022 Marzo 56 49 105
2022 Febrero 51 29 80
2022 Enero 62 33 95
2021 Diciembre 50 33 83
2021 Noviembre 62 43 105
2021 Octubre 80 54 134
2021 Septiembre 62 41 103
2021 Agosto 51 25 76
2021 Julio 49 15 64
2021 Junio 54 21 75
2021 Mayo 33 34 67
2021 Abril 90 44 134
2021 Marzo 90 24 114
2021 Febrero 55 22 77
2021 Enero 38 13 51
2020 Diciembre 35 20 55
2020 Noviembre 21 17 38
2020 Octubre 22 4 26
2020 Septiembre 27 8 35
2020 Agosto 32 16 48
2020 Julio 16 21 37
2020 Junio 28 25 53
2020 Mayo 19 14 33
2020 Abril 25 9 34
2020 Marzo 19 12 31
2020 Febrero 3 2 5
Mostrar todo

Siga este enlace para acceder al texto completo del artículo

Idiomas
Actas Dermo-Sifiliográficas
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?